Filing Flows › Krystal Biotech (KRYS) › Free cash flow
Krystal Biotech (KRYS) free cash flow by quarter
Krystal Biotech's free cash flow was $90.3M in Q3 2026 (third quarter 2026), +27% from Q2 2026. Over the last 7 quarters it ranged from $24.8M (Q1 2025) to $90.3M (Q3 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $90.3M | +27% | +138% |
| Q2 2026 | $71.2M | -3% | +40% |
| Q1 2026 | $73.2M | -3% | +196% |
| Q4 2025 | $75.4M | +99% | — |
| Q3 2025 | $38.0M | -25% | — |
| Q2 2025 | $50.8M | +105% | — |
| Q1 2025 | $24.8M | — | — |
Q3 2026 at a glance
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Krystal Biotech's free cash flow?
Krystal Biotech's free cash flow was $90.3M in Q3 2026 (third quarter 2026), +27% from Q2 2026.
How has Krystal Biotech's free cash flow changed?
Over the last 7 quarters it ranged from $24.8M (Q1 2025) to $90.3M (Q3 2026).